Drugs / Keytruda-EU
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06159790 Comparator | Apr 2024 → Mar 2026 | non-small cell lung carcinoma | Sandoz | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Keytruda-EU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06159790 ↗ |
| Known as | pembrolizumab | “EU-authorized pembrolizumab (Keytruda-EU)” NCT06159790 ↗ |
| Modality | Protein / enzyme biologic | “Concentrate for solution for infusion, biologic, liquid in vial” NCT06159790 ↗ |
| Route | Intravenous | “i.v. infusion” NCT06159790 ↗ |